Sanofi Signs Antibiotics Research Collaboration Deal

Sanofi signs a research collaboration with Rib-X Pharmaceuticals to develop novel antibiotics.

French pharma giant Sanofi has established a worldwide research collaboration with Rib-X Pharmaceuticals to develop novel antibiotics.

The agreement also includes an option to licence the drugs resulting from Rib-X's RX-04 program, used to treat resistant Gram-positive and Gram-negative pathogens.

According to the agreement, Rib-X will receive an upfront payment of $10m and will be eligible to receive a further $9m relating to milestone payments relating to research, pre-clinical, regulatory and commercial milestones.

Sanofi will retain the right to develop multiple products under the agreement, whereas Rib-X will keep its rights to the discover